Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_30_3614 - Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer
H. LI1, V. Verma2, E. D. Brooks3, L. Feng1, T. Zhang4, J. W. Welsh3, S. H. Lin5, D. R. Gomez5, S. Gandhi3, J. Heymach3, and J. Y. Chang3; 1The University of Texas MD Anderson Cancer Center, HOUSTON, TX, 2Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, 3The University of Texas MD Anderson Cancer Center, Houston, TX, 4Texas University MD Anderson Cancer Center, Houston, TX, 5Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Purpose/Objective(s): Because radiotherapy (RT) induces beneficial antitumoral immune responses, administering corticosteroids (CS) for other medical issues such as COPD, RT-related toxicity attenuation, is a major oncologic concern. This is the only known study evaluating the impact of CS on outcomes of early-stage non-small cell lung cancer (NSCLC) following stereotactic ablative RT (SABR).

Materials/Methods: A prospectively-registered institutional database of SABR for early-stage non-metastatic NSCLC was queried (2005-2015). CS administration (non-inhaled, regardless of dose/agent) was dichotomized based on two definitions: 1) CS receipt within two days of the SABR course, and 2) CS delivery between up to 6 months before SABR and the date of last follow-up or any progressive disease (LFU/PD). Statistics included Kaplan-Meier survival analysis, Cox proportional hazards modeling, and cumulative incidence analysis utilizing death as a competing risk model evaluated with Gray’s test.

Results: Of 912 consecutive patients, 87 (10%) received CS based on the ± 2-day definition, and 211 (23%) based on the LFU/PD definition. The most common CS agents were prednisone (62%) and dexamethasone (19%); most common CS indications were COPD (34%) and pneumonitis caused by SABR or other previous treatments (24%). Median follow-up was 45 months. Groups were largely well-balanced. Patients receiving CS appears to have a significant change in blood white cell parameters. Although CS administration associated with worse isolated locoregional recurrence-free survival, distant metastasis-free survival, recurrence-free survival, and overall survival on Kaplan-Meier and Cox multivariate analysis, there were no differences in cumulative incidences of recurrence (local, regional, isolated locoregional, distant, any) when using death as a competing risk model, in both CS delivery definitions (p>0.05 for all).

Conclusion: Although further corroboration is required and causation is not implied, these data do not suggest a detriment in outcomes if corticosteroids are administered in proximity with SABR. Individualized judgment in administering CS for these settings is still recommended. These data have implications not only for ongoing cooperative group trials, but also the construction and implementation of immunotherapy-SABR trials.

Author Disclosure: H. LI: None. V. Verma: None. E.D. Brooks: None. L. Feng: None. J.W. Welsh: Stock; Healios, MolecularMatch. Stock Options; OncoResponse, Reflexion Medical. S.H. Lin: Research Grant; Elekta, Inc, Hitachi Chemical, Inc, Peregrine Pharmaceuticals, Inc, Roche/Genentech, STCube Pharmaceuticals, Inc. D.R. Gomez: Research Grant; Merck, AstraZeneca. Honoraria; BMS. Speaker's Bureau; Merck, Varian. Advisory Board; AstraZeneca. S. Gandhi: None. J. Heymach: None. J.Y. Chang: Research Grant; MDACC-BMS Alliance Research Grant. Partnership; Global Oncology One. Chair of the Board of Directors; SANTRO. Chair; ACR. Chair for Thoracic Subcommittee; PTCOG.

Send Email for Hongqi LI


Assets

TU_30_3614 - Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer